Yang J, Zhang L, Guo M, Hao M (2023) Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure. Medicine 102(45):e35900

Article  PubMed  PubMed Central  CAS  Google Scholar 

Urbaszek W (1991) Definition und klassifikation der herzinsuffizienz. Zeitschrift für Kardiologie 80:7–12

PubMed  Google Scholar 

Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A (2004) The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 13(2):163–170

Article  PubMed  CAS  Google Scholar 

Trullàs JC, Morales-Rull JL, Formiga F (2013) Diuretic therapy in heart failure. Med Clin 142(4):163–170

Article  Google Scholar 

Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9(10):1064–1069

Article  PubMed  CAS  Google Scholar 

Bhatt PR, McNeely EB, Lin TE, Adams KF Jr, Patterson JH (2014) Review of tolvaptan’s pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med 3(4):1276–1290

Article  PubMed  PubMed Central  Google Scholar 

Lin TE, Adams KF, Patterson JH (2014) Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. Heart Fail Clin 10(4):607–620

Article  PubMed  Google Scholar 

Dixon MB, Lien YH (2008) Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag 4(6):1149–1155

PubMed  PubMed Central  CAS  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) Cochrane bias methods group; cochrane statistical methods group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784

Article  PubMed  Google Scholar 

Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C (2012) Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med 13(7):415–422

Article  CAS  Google Scholar 

Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67(5):399–405. https://doi.org/10.1016/j.jjcc.2015.09.020

Article  PubMed  Google Scholar 

Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22(6):423–432. https://doi.org/10.1016/j.cardfail.2016.02.007

Article  PubMed  CAS  Google Scholar 

Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, Kawasaki M, Kikuchi A, Kondo T, Ozaki T, Seo M, Ikeda I, Fukuhara E, Abe M, Nakamura J, Fukunami M (2017) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction - prospective randomized controlled study. Circ J 81(5):740–747. https://doi.org/10.1253/circj.CJ-16-1122

Article  PubMed  CAS  Google Scholar 

Nomoto H, Satoh Y, Kamiyama M, Yabe K, Masumura M, Sakakibara A, Yamashita S, Suzuki M, Sugiyama T, Oumi T, Ohno M, Takahashi Y, Isobe M (2017) Mechanisms of diuresis for acute decompensated heart failure by tolvaptan. Int Heart J 58(4):593–600. https://doi.org/10.1536/ihj.16-438

Article  PubMed  Google Scholar 

Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, Shibagaki Y (2017) Effects of tolvaptan addition to furosemide in normo- and hyponatremia patients with heart failure and chronic kidney disease stages G3b–5: a subanalysis of the K-STAR study. Am J Nephrol 46(5):417–426. https://doi.org/10.1159/000481995

Article  PubMed  CAS  Google Scholar 

Komiya S, Katsumata M, Ozawa M, Haze T, Kawano R, Ohki Y, Suzuki S, Kobayashi Y, Fujiwara A, Saka S (2022) Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial. Clin Exp Nephrol 26(9):851–858

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cice G (2019) Renal insufficiency in acute heart failure: old habits we need to let go? Eur Heart J Suppl 21:B38–B42

Article  PubMed  PubMed Central  Google Scholar 

Schefold JC, Filippatos G, Hasenfuss G, Anker SD, Von Haehling S (2016) Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 12(10):610–623

Article  PubMed  CAS  Google Scholar 

Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47(10):1987–1996

Article  PubMed  Google Scholar 

Banerjee D, Rosano G, Herzog CA (2021) Management of heart failure patient with CKD. Clin J Am Soc Nephrol 16(7):1131–1139

Article  PubMed  PubMed Central  CAS  Google Scholar 

Masarone D, Martucci ML, Errigo V, Pacileo G (2021) The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 8(9):101

PubMed  PubMed Central  CAS  Google Scholar 

Humphrey TJ, James G, Wittbrodt ET, Zarzuela D, Hiemstra TF (2021) Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J 14(10):2203–2212

Article  PubMed  PubMed Central  CAS  Google Scholar 

Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A (2002) Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 82(2):149–158

Article  PubMed  CAS  Google Scholar 

Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM (2020) Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 75(10):1178–1195

Article  PubMed  CAS  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J (2024) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 26(1):5–17

Article  PubMed  Google Scholar 

Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WW, Orso F, Rossignol P (2019) The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155

Article  PubMed  Google Scholar 

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–e161

Article  PubMed  Google Scholar 

Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T (2017) Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J 81(11):1736–1738

Article  PubMed  Google Scholar 

Wang C, Xiong B, Cai L (2017) Effects of tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 17:1–11

Article  PubMed  PubMed Central  Google Scholar 

Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J, Rong S, Deng S, Cao Y, Zou Y (2015) The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev 20:633–642